ALIM Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (1 Jul 2024 @ 16:00):
Our systems believe the stock currently is overvalued by -0.20% compare to its pairs and should correct downwards.

Alimera Sciences, Inc., a pharmaceutical company, engages in the development and commercialization of ophthalmic pharmaceuticals in the United States and internationally...

Stats
Today's Volume	256 965
Average Volume	303 220
Market Cap	289.18M
EPS	$-0.110 ( Q1 \| 2024-05-14 )
Next earnings date	( $-0.0300 ) 2024-08-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-22.08 (Sector) 42.63 (Industry) 0
ATR14	$0.00500 (0.09%)

ACOR -24.02%

ACRX 7.50%

ADMP 0.85%

ADMS 0.00%

AGRX 0.71%

AKAN -2.16%

ALIM -0.72%

AMPH -3.73%

AMYT 0.00%

ANIP -0.38%

AQST -5.77%

ASRT -4.03%

ATNX 0.00%

AVDL 0.43%

AYTU -2.06%

BFRI -0.67%

BGXX 8.76%

CLVR -1.52%

COLL 1.30%

CPIX -3.27%

CRDL -0.99%

CRON -1.29%

CYTH -5.51%

DCPH 0.00%

DERM -4.79%

DRRX 1.55%

DVAX -0.62%

EGRX -1.25%

EMBC -2.80%

EMBCV -9.33%

EOLS 2.12%

ESPR 5.41%

EVOK -10.81%

FLGC -2.94%

FLXN 0.00%

GHSI -2.08%

HCM 2.57%

HROW 0.77%

HUGE -14.49%

IMCC -3.43%

INCR 1.00%

IRWD 0.00%

ITCI -0.73%

IXHL 0.34%

JUPW 11.76%

KALA -2.82%

KIN 0.11%

KMDA -3.40%

LNTH -0.36%

NBIX 1.77%

NEPT 0.00%

NLTX 1.45%

OGI 0.00%

OPTN 0.96%

ORGO -3.57%

PAHC 1.61%

PCRX -0.52%

PETQ 3.67%

PLXP 0.00%

PPD 0.00%

PROC 3.16%

PRPH -2.87%

PTPI -5.66%

RDHL -2.00%

RDUS 0.13%

REPH -0.48%

RGC -5.03%

RMTI -5.11%

SCTL 0.92%

SCYX -2.50%

SIGA -0.53%

SISI -14.23%

SNDL 1.05%

SNOA 8.44%

SSIC -2.37%

SUPN -0.75%

SXTC -2.79%

THTX -1.41%

TKNO -11.68%

TLGT -13.85%

TLRY 1.20%

TXMD 6.21%

TYHT -3.90%

UPC 2.08%

VTRS -0.38%

ZYNE 2.36%

Insider Trading

Date	Person	Action	Amount	type
2024-03-26	Ashman Philip	Sell	12 103	Common Stock
2024-03-11	Werner Jason M.	Buy	1 800	Restricted Stock Units
2024-03-11	Wood Todd Michael	Buy	125 000	Performance-Based Restricted Stock Units
2024-03-11	Wood Todd Michael	Buy	125 000	Restricted Stock Units
2024-03-11	Eiswirth Richard S Jr	Buy	14 700	Restricted Stock Units

INSIDER POWER
27.24
Last 77 transactions
Buy: 33 555 909 \| Sell: 20 075 544

Correlation (AI algo v.1.1b): Overvalued: -0.20% $5.53 paired level. (The Algo Track The Changes Of The Most Correlated Stocks In Realtime And Give An Instant Update)

Volume Correlation

Long: -0.10 (neutral)

Short: 0.63 (weak)

Signal:(46.406) Neutral

Alimera Sciences Inc Correlation

10 Most Positive Correlations
OZEM	1
RIGL	0.802

10 Most Negative Correlations
RTC	-0.809

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Alimera Sciences Inc Correlation - Currency/Commodity

0.00
( neutral )

-0.07
( neutral )

Alimera Sciences Inc Financials

Annual	2023
Revenue:	$80.75M
Gross Profit:	$61.17M (75.75 %)
EPS:	$-0.790

FY	2023
Revenue:	$80.75M
Gross Profit:	$61.17M (75.75 %)
EPS:	$-0.790

FY	2022
Revenue:	$54.13M
Gross Profit:	$46.15M (85.26 %)
EPS:	$-2.59

FY	2021
Revenue:	$59.03M
Gross Profit:	$52.00M (88.09 %)
EPS:	$-0.854

Financial Reports:

No articles found.

Alimera Sciences Inc Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Alimera Sciences Inc

Alimera Sciences, Inc., a pharmaceutical company, engages in the development and commercialization of ophthalmic pharmaceuticals in the United States and internationally. It offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye. The company sells its products to physician offices, pharmacies, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. for the development and sale of insert technology to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans or to treat diabetic macular edema. The company was incorporated in 2003 and is headquartered in Alpharetta, Georgia.